Search company, investor...
Search
CONTINUUS Pharmaceuticals company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

continuuspharma.com

Founded Year

2012

Stage

Loan | Alive

Total Raised

$8.45M

Last Raised

$680K | 2 yrs ago

About CONTINUUS Pharmaceuticals

CONTINUUS Pharmaceuticals offers an integrated continuous manufacturing technology that produces medicines at significantly costs, with reduced lead times, and of better quality, utilizing ICM technology.

CONTINUUS Pharmaceuticals Headquarters Location

25-R Olympia Avenue

Woburn, Massachusetts, 01801,

United States

781-281-0226

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing CONTINUUS Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CONTINUUS Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CONTINUUS Pharmaceuticals Patents

CONTINUUS Pharmaceuticals has filed 3 patents.

The 3 most popular patent topics include:

  • Chemical processes
  • Manufacturing
  • Separation processes
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/3/2017

5/24/2022

Filters, Separation processes, Chemical processes, Manufacturing, Environmental engineering

Grant

Application Date

2/3/2017

Grant Date

5/24/2022

Title

Related Topics

Filters, Separation processes, Chemical processes, Manufacturing, Environmental engineering

Status

Grant

Latest CONTINUUS Pharmaceuticals News

MIT spinout Continuus calls upon Skanska to build MA site with federal defense money

Jan 6, 2022

Josh Sullivan Associate Editor A spin­out from an MIT lab has land­ed a deal with a Swedish de­vel­op­ment group to build a $125 mil­lion man­u­fac­tur­ing fa­cil­i­ty in Woburn, MA, just 15 miles out­side Boston. Skan­s­ka signed a con­tract with Con­tin­u­us Phar­ma­ceu­ti­cals to ren­o­vate and build an­oth­er 50,000 square foot site up to cur­rent Good Man­u­fac­tur­ing Prac­tices stan­dards that will pro­duce dry ac­tive phar­ma­ceu­ti­cal in­gre­di­ents and fin­ished drug prod­ucts in both ster­ile in­jectable and tablets forms. Con­tin­u­us is de­vel­op­ing a new plat­form it calls In­te­grat­ed Con­tin­u­ous Man­u­fac­tur­ing. This en­ables end-to-end drug pro­duc­tion and us­es the syn­the­sis of APIs and the fi­nal dosage form as a sin­gle seam­less process. The com­pa­ny was found­ed in 2012 and has raised $7.7 mil­lion so far, $5 mil­lion of which came from a 2019 Se­ries B. Three crit­i­cal care med­i­cines and an ad­di­tion­al key drug will be made there to start, though Skan­s­ka says it will have room for growth. Con­tin­u­us spe­cial­izes in small-mol­e­cule phar­ma­ceu­ti­cals, and as re­cent­ly as Ju­ly opened a new 3,000-square-foot lab that holds clean room space and high-po­ten­cy ca­pa­bil­i­ties. That came half a year af­ter the com­pa­ny an­nounced it land­ed a $69 mil­lion con­tract from the De­part­ment of De­fense to make med­i­cines to treat crit­i­cal­ly ill pa­tients, in­clud­ing those with Covid-19. That was the sec­ond gov­ern­ment deal award­ed to Con­tin­u­us. The com­pa­ny pre­vi­ous­ly signed on with the FDA to help es­tab­lish a sci­ence-based ap­proach to cre­at­ing reg­u­la­to­ry guide­lines for con­tin­u­ous man­u­fac­tur­ing. “Our new lab space, lo­cat­ed one mile from our cur­rent man­u­fac­tur­ing site and cor­po­rate head­quar­ters, will help Con­tin­u­us ad­vance our mis­sion for on-de­mand de­liv­ery of af­ford­able, high-qual­i­ty, vi­tal med­i­cines to pa­tients in need of ther­a­peu­tic so­lu­tions, and will al­so help fa­cil­i­tate col­lab­o­ra­tions with in­no­va­tor com­pa­nies that are de­vel­op­ing high-po­ten­cy drugs,” CEO Sal­va­tore Mas­cia said. Skan­s­ka re­cent­ly was as­signed to de­vel­op As­traZeneca’s Cam­bridge, UK R&D op­er­a­tions in 2020, but was re­placed by Mace af­ter As­traZeneca said the lat­ter had more ex­per­tise in the sci­en­tif­ic fit-out and com­mis­sion­ing. That project was plagued by de­lays, thanks to de­sign and roof load­ing is­sues. Most re­cent­ly, Skan­s­ka com­plet­ed the con­struc­tion of Vir­ginia Hos­pi­tal Cen­ter’s newest out­pa­tient pavil­ion in Ar­ling­ton. Con­struc­tion in Woburn be­gan in Oc­to­ber 2021 and is sched­uled to wrap up in Q2 of this year. Ed­i­tor’s Note: For more news and ex­clu­sive cov­er­age from the man­u­fac­tur­ing beat, sub­scribe to the End­points Man­u­fac­tur­ing week­ly re­port in your read­er pro­file. AUTHOR It’s big days for biology. The pandemic has seen a series of very public scientific breakthroughs: mRNA vaccine, Covid antibodies, CRISPR as therapy. The minds behind these advancements have graced magazine covers and received prestigious awards. But the last two years have also, far more quietly, seen a series of new experiments in how to fund the next generation of scientific breakthroughs. Since March 2020, investors, academics, a significant number of Silicon Valley types, at least one Russian billionaire and two crypto billionaires and, most recently, a few West Coast universities have launched a series of grant programs, institutes, NGOs and companies hoping to change how life science research is done. Though unaffiliated and varying greatly in both size and form, they have broadly promised to evade bureaucracy and misaligned incentives and advance both basic and not-so-basic research in ways they say can’t be done in either conventional academia or profit-focused biotech. Keep reading Endpoints with a free subscription Unlock this story instantly and join 127,400+ biopharma pros reading Endpoints daily — and it's free. SIGN UP John Carroll Editor & Founder Bursting at the seams and executing plans for swift expansion to support its manufacturing work for the mRNA vaccine out of Pfizer/BioNTech, Indianapolis-based Exelead has now been scooped up in a $780 million cash buyout deal. Germany’s Merck KGaA, which bought out another mRNA manufacturer, AmpTec, early last year, has been beefing up its ops around lipids, which, in mRNA vaccines, play a key role in turning human cells into a mini—vaccine factories? Keep reading Endpoints with a free subscription Unlock this story instantly and join 127,400+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Zachary Brennan Senior Editor For anyone who’s been following how the US government has been allocating and shipping supplies of its Covid-19 treatments over the past year, the news has shifted so many times that it can be difficult to keep track of what’s still being shipped and where. More change is coming this week too, as HHS has now decided to re-start shipments of both Eli Lilly (bamlanivimab plus etesevimab) and Regeneron (casirivimab plus imdevimab) monoclonal antibody products after a short pause because neither product works against the new variant Omicron. Lilly’s combo also was halted last June due to the presence of other variants. Read More Kyle Blankenship Managing Editor After a down year, biopharma writ large is looking for a breath of fresh air — and now the winds of change have hit oncology bispecifics player Zymeworks. Ali Tehrani, a co-founder of Zymeworks who has been the biotech’s CEO since 2003, has resigned from his position and will be replaced by Ken Galbraith, a serial biotech entrepreneur and former board member, the company said Wednesday. Tehrani will take on an advisory role with the company once his tenure formally ends Feb. 1 to help aid in the transition for Galbraith’s leadership turn. Meanwhile, board chair Lota Zoth will be moved into an independent director role in conjunction with the shakeup. Read More

CONTINUUS Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

CONTINUUS Pharmaceuticals Rank

  • When was CONTINUUS Pharmaceuticals founded?

    CONTINUUS Pharmaceuticals was founded in 2012.

  • Where is CONTINUUS Pharmaceuticals's headquarters?

    CONTINUUS Pharmaceuticals's headquarters is located at 25-R Olympia Avenue, Woburn.

  • What is CONTINUUS Pharmaceuticals's latest funding round?

    CONTINUUS Pharmaceuticals's latest funding round is Loan.

  • How much did CONTINUUS Pharmaceuticals raise?

    CONTINUUS Pharmaceuticals raised a total of $8.45M.

  • Who are the investors of CONTINUUS Pharmaceuticals?

    Investors of CONTINUUS Pharmaceuticals include Paycheck Protection Program, Mark Bamforth, IMA Group, Oxford Bioscience Partners and MassChallenge.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.